Skip to main content

Table 4 Pathways significantly represented in the single lines

From: Displayed correlation between gene expression profiles and submicroscopic alterations in response to cetuximab, gefitinib and EGF in human colon cancer cell lines

Treatment type

p-val

Pathway affected

HT-29

  

E

0,0127

Parkinson's disease

 

0,0216

Bisphenol A degradation

 

0,027

Nucleotide sugars metabolism

 

0,028

ECM-receptor interaction

 

0,029

Ubiquitin mediated proteolysis

 

0,03

Neurodegenerative disorders

 

0,03

Prion disease

 

0,03

mTOR signaling pathway

Cx10

0,0001

Ribosome

 

0,0288

Calcium signaling pathway

 

0,0467

Prion disease

Gb

0,0056

T cell receptor signaling pathway

 

0,0115

mTOR signaling pathway

 

0,0163

Natural killer cell mediated cytotoxicity

 

0,0187

Pentose and glucuronate interconversions

 

0,0202

Tight junction

 

0,0214

Starch and sucrose metabolism

 

0,0242

Insulin signaling pathway

 

0,0293

Long-term potentiation

 

0,0332

GnRH signaling pathway

 

0,0352

TGF-beta signaling pathway

 

0,0402

MAPK signaling pathway

 

0,0482

D-Glutamine and D-glutamate metabolism

 

0,0497

Cell Communication

Cx10 + E

0,0001

Oxidative phosphorylation

 

0,0211

Benzoate degradation via hydroxylation

 

0,0254

Chronic myeloid leukemia

 

0,0277

Antigen processing and presentation

 

0,0319

Ribosome

 

0,0461

Notch signaling pathway

Gb + E

0,0002

Cholera – Infection

 

0,0003

PPAR signaling pathway

 

0,0075

Tyrosine metabolism

 

0,0090

Fluorene degradation

 

0,0126

Benzoate degradation via hydroxylation

 

0,0197

Insulin signaling pathway

 

0,0205

Fatty acid metabolism

 

0,0208

Calcium signaling pathway

 

0,0225

Neuroactive ligand-receptor interaction

 

0,0338

Oxidative phosphorylation

 

0,0351

Glycerolipid metabolism

 

0,0385

Glioma

 

0,0428

Urea cycle and metabolism of amino groups

 

0,0442

Neurodegenerative disorders

 

0,0442

Styrene degradation

 

0,0442

Fatty acid biosynthesis

 

0,0445

1- and 2-Methylnaphthalene degradation

Caco-2

  

E

0,0022

Epithelial cell signaling in Helicobacter pylori infection

 

0,0034

Tight junction

 

0,0133

Adherent junction

 

0,0152

Dentatorubropallidoluysian atrophy (DRPLA)

 

0,0179

Apoptosis

 

0,0422

Methionine metabolism

 

0,0436

D-Glutamine and D-glutamate metabolism

 

0,0445

Selenoamino acid metabolism

 

0,0481

Glycan structures – biosynthesis 2

 

0,0496

Toll-like receptor signaling pathway

Cx10

0,0008

Oxidative phosphorylation

 

0,0134

Ribosome

 

0,0179

Cell cycle

 

0,0193

Metabolism of xenobiotics by cytochrome P450

 

0,0356

Glycan structures – biosynthesis 1

 

0,0489

O-Glycan biosynthesis

Gb

0,0001

Ribosome

 

0,0106

Basal cell carcinoma

 

0,0135

Cell Communication

 

0,0308

Valine, leukine and isoleukine degradation

 

0,0394

Fatty acid metabolism

Cx10 + E

0.0141

Gap junction

 

0.0163

GnRH signaling pathway

 

0.0169

ECM-receptor interaction

 

0.0364

Vitamin B6 metabolism

Gb + E

0,0183

C5-Branched dibasic acid metabolism

 

0,0369

Tight junction

  1. E = Epidermal growth factor 10 nmol/L; Cx10 = cetuximab 10 nmol/L; Gb = gefitinib. 1 μmol/L;
  2. Cx10 + E = cetuximab 10 nmol/L + Epidermal growth factor 10 nmol/L; Gb + E = gefitinib 1 μmol/L + Epidermal growth factor 10 nmol/L. The pathways were considered significant if P ≤ 0.05.